Septerna, Inc.
SEPN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.8B
Close$
$-33.12
174.9% downside
Current Fair Value
174.9% downsideOvervalued by 174.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.80 Billion |
|---|---|
| Enterprise Value | $1.82 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.1 |
| Beta | 2.28 |
| Outstanding Shares | 45,040,075 |
Return
| Return on Equity | -6.27% |
|---|---|
| Return on Assets | -4.28% |
| Return on Invested Capital | -10.52% |
Valuation & Multiples
| P/E Ratio | -74.07 |
|---|---|
| PEG | 155.87 |
| Price to Sales | 22.1 |
| Price to Book Ratio | 5.53 |
| Enterprise Value to Revenue | 18.42 |
| Enterprise Value to EBIT | -35.53 |
| Enterprise Value to Net Income | -76 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
$19.22 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
$19.22 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3782▲ 37.82% |
|---|---|
| Total Calls | 1,041,000▲ 1326.03% |
| Total Puts | 393,752▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 105.92%▲ 3.76% |
|---|---|
| Total Invested | $1.59B▲ 44.49% |
| Investors Holding | 164▲ 39.00% |
ESG Score
No data
About Septerna, Inc.
75 employees
CEO: Dr. Jeffrey T. Finer M.D., Ph.D. Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic disea...